Overcoming drug resistance in chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Imatinib therapy yields excellent clinical results in chronic myeloid leukemia (CML).
• However, most CML patients maintain minimal residual disease, and some develop resistance, leading to disease progression.
• There is a critical need for novel strategies to overcome and prevent imatinib resistance in CML.

Purpose of the Study:

• To review emerging therapeutic approaches for imatinib-resistant chronic myeloid leukemia.
• To highlight the development of new agents and immunomodulatory strategies for CML treatment.
• To discuss the future challenges in eradicating CML and achieving a cure.

Main Methods:

• Review of recent preclinical and clinical studies on novel agents for CML.
• Analysis of tyrosine kinase inhibitors (TKIs), hypomethylating agents, farnesyl transferase inhibitors, and homoharringtonine.
• Exploration of immunomodulatory approaches, including vaccines, for CML treatment.

Main Results:

• Several novel agents demonstrate significant activity against imatinib-resistant CML.
• Second-generation TKIs, including those with dual Abl and Src activity, show impressive results.
• Other agents like hypomethylating agents, farnesyl transferase inhibitors, homoharringtonine, and therapeutic vaccines show preclinical and clinical promise.

Conclusions:

• Multiple effective agents are in development to overcome imatinib resistance in CML.
• The integration of these agents into treatment strategies is crucial for disease elimination.
• The ultimate goal is to achieve a cure for all patients with chronic myeloid leukemia.